Kidney disease in patients with chronic liver disease
10.5124/jkma.2020.63.1.14
- Author:
Jae Hyun CHANG
1
Author Information
1. Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. jhchang@gilhospital.com
- Publication Type:Original Article
- Keywords:
Chronic disease;
Liver diseases;
Hepatitis B virus;
Hepatitis C virus;
Kidney diseases
- MeSH:
Antiviral Agents;
Carcinoma, Hepatocellular;
Chronic Disease;
Fibrosis;
Hepacivirus;
Hepatitis;
Hepatitis B virus;
Humans;
Kidney Diseases;
Kidney Failure, Chronic;
Kidney;
Liver Diseases;
Liver;
Renal Dialysis;
Renal Insufficiency, Chronic
- From:Journal of the Korean Medical Association
2020;63(1):14-19
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The kidneys are closely connected with several organs, including the liver, and can therefore be negatively affected when the liver is damaged. The most common cause of chronic liver disease is chronic viral hepatitis, resulting from either a hepatitis B virus (HBV) or a hepatitis C virus (HCV). Chronic viral hepatitis often progresses to cirrhosis and hepatocellular carcinoma. However, it can also lead to viral-associated glomerulopathies that can cause chronic kidney disease (CKD), which can then progress to end stage renal disease (ESRD). Additionally, patients with ESRD on hemodialysis are at risk for viral infections because HBV and HCV are hematogenously transmitted. Recently, treatments with oral nucleoside/nucleotide analogues and direct-acting antivirals have yielded excellent results in HBV- and HCV-infected patients with CKD. As a result, a new paradigm for the treatment of chronic viral infections in CKD patients has emerged. This review discusses viral-associated glomerulopathies, antiviral treatments of HBV and HCV infections in patients with CKD, and prevention strategies for the transmission of HBV and HCV in patients with ESRD.
